Literature DB >> 16439683

Mobilization as a preparative regimen for hematopoietic stem cell transplantation.

Jing Chen1, André Larochelle, Simon Fricker, Gary Bridger, Cynthia E Dunbar, Janis L Abkowitz.   

Abstract

Current myeloablative conditioning regimens for hematopoietic stem cell (HSC) transplantation are associated with significant morbidity and mortality. Thus, alternative strategies to promote engraftment of infused HSCs with increased safety warrant investigation. Using parabiotic mice, we determined that, after mobilization with AMD3100 (a CXCR4 antagonist), HSCs exited from marrow, transited blood, and engrafted in open niches in partner marrow. We then hypothesized that mobilization before transplantation might vacate niches and improve HSC engraftment. When PeP3(b) mice were treated with AMD3100 at 2 hours before the transplantation of 4 x 10(7) marrow cells, donor cell engraftment was higher (4.6% +/- 1.1%) than in control animals (no AMD3100; 1.0% +/- 0.24%, P < .001). When mice received weekly injections of AMD3100 on 3 consecutive weeks and marrow cells were transplanted 2 hours after each mobilization, donor cell engraftment further increased (9.1% +/- 1.7%, P = .001). In contrast, in similar experiments with Balb/cByJ mice that mobilize poorly, there was no difference between the donor cell engraftment of AMD3100-treated and control recipients. These results indicate that the number of available niches regulates the number of HSCs. In addition, mobilization with AMD3100 may provide a safer preparative approach for HSC transplantation in genetic and other nonmalignant disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439683      PMCID: PMC1895779          DOI: 10.1182/blood-2005-09-3593

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.

Authors:  E De Clercq; D Schols
Journal:  Antivir Chem Chemother       Date:  2001

2.  Host marrow stem cell potential and engraftability at varying times after low-dose whole-body irradiation.

Authors:  F M Stewart; S Zhong; J F Lambert; G A Colvin; M Abedi; M S Dooner; C I McAuliffe; H Wang; C Hsieh; P J Quesenberry
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

3.  The effects of SCF/G-CSF prestimulation on radiation sensitivity and engraftment in nonmyeloablated murine hosts.

Authors:  N Giri; A Kaushiva; T Wu; S E Sellers; J F Tisdale
Journal:  Exp Hematol       Date:  2001-06       Impact factor: 3.084

4.  Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers.

Authors:  C W Hendrix; C Flexner; R T MacFarland; C Giandomenico; E J Fuchs; E Redpath; G Bridger; G W Henson
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  In vivo kinetics of murine hemopoietic stem cells.

Authors:  J L Abkowitz; D Golinelli; D E Harrison; P Guttorp
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

6.  Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure.

Authors:  Janis L Abkowitz; Abigail E Robinson; Sujata Kale; Michael W Long; Jing Chen
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

7.  Evidence that the number of hematopoietic stem cells per animal is conserved in mammals.

Authors:  Janis L Abkowitz; Sandra N Catlin; Monica T McCallie; Peter Guttorp
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

8.  Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.

Authors:  W Conrad Liles; Hal E Broxmeyer; Elin Rodger; Brent Wood; Kai Hübel; Scott Cooper; Giao Hangoc; Gary J Bridger; Geoffrey W Henson; Gary Calandra; David C Dale
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

9.  CD45 tyrosine phosphatase inhibits erythroid differentiation of umbilical cord blood CD34+ cells associated with selective inactivation of Lyn.

Authors:  Akira Harashima; Motoyuki Suzuki; Ayumi Okochi; Mayuko Yamamoto; Yoshinobu Matsuo; Ryuichi Motoda; Tamotsu Yoshioka; Kunzo Orita
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

10.  Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.

Authors:  Steven M Devine; Neal Flomenberg; David H Vesole; Jane Liesveld; Daniel Weisdorf; Karin Badel; Gary Calandra; John F DiPersio
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

View more
  37 in total

Review 1.  Getting blood from bone: an emerging understanding of the role that osteoblasts play in regulating hematopoietic stem cells within their niche.

Authors:  Yusuke Shiozawa; Russell S Taichman
Journal:  Exp Hematol       Date:  2012-05-26       Impact factor: 3.084

2.  Studies of c-Mpl function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones.

Authors:  Janis L Abkowitz; Jing Chen
Journal:  Blood       Date:  2007-03-08       Impact factor: 22.113

Review 3.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

Review 4.  Physiology and pharmacology of plerixafor.

Authors:  Simon P Fricker
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

5.  Hematopoietic stem cells proliferate until after birth and show a reversible phase-specific engraftment defect.

Authors:  Michelle B Bowie; Kristen D McKnight; David G Kent; Lindsay McCaffrey; Pamela A Hoodless; Connie J Eaves
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

6.  Inhibiting stromal cell heparan sulfate synthesis improves stem cell mobilization and enables engraftment without cytotoxic conditioning.

Authors:  Borja Saez; Francesca Ferraro; Rushdia Z Yusuf; Colleen M Cook; Vionnie W C Yu; Ana Pardo-Saganta; Stephen M Sykes; Rahul Palchaudhuri; Amir Schajnovitz; Sutada Lotinun; Stefania Lymperi; Simon Mendez-Ferrer; Raquel Del Toro; Robyn Day; Radovan Vasic; Sanket S Acharya; Roland Baron; Charles P Lin; Yu Yamaguchi; Amy J Wagers; David T Scadden
Journal:  Blood       Date:  2014-09-08       Impact factor: 22.113

7.  Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia Cells.

Authors:  Chen Glait-Santar; Ronan Desmond; Xingmin Feng; Taha Bat; Jichun Chen; Elisabeth Heuston; Benjamin Mizukawa; James C Mulloy; David M Bodine; Andre Larochelle; Cynthia E Dunbar
Journal:  Stem Cells       Date:  2015-10-05       Impact factor: 6.277

8.  Modeling promising nonmyeloablative conditioning regimens in nonhuman primates.

Authors:  Devikha Chandrasekaran; Betty Nakamoto; Korashon L Watts; Hans-Peter Kiem; Thalia Papayannopoulou
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

9.  Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model.

Authors:  Yubin Kang; Benny J Chen; Divino Deoliveira; Jeffrey Mito; Nelson J Chao
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

10.  Niche recycling through division-independent egress of hematopoietic stem cells.

Authors:  Deepta Bhattacharya; Agnieszka Czechowicz; A G Lisa Ooi; Derrick J Rossi; David Bryder; Irving L Weissman
Journal:  J Exp Med       Date:  2009-11-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.